Clinical Trial Update: Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial investigating anti-HER2 therapy combined with fulvestrant/capecitabine for HR+, HER2+, non-visceral metastatic breast cancer; status not yet recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anti-HER2 Therapy
• Capecitabine (capecitabine)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING